Tebon Securities
Search documents
有色金属行业周报:美降息渐进,贵金属走强
Tebon Securities· 2024-09-16 12:23
[Table_Main] 证券研究报告 | 行业周报 有色金属 2024 年 09 月 16 日 | --- | --- | |------------------|------------------------------| | | | | | | | | | | 有色金属 | 有色金属周报:美降息渐进,贵 | | | | | 优于大市(维持) | | [Table_Summary] 投资要点: 金属走强 证券分析师 翟堃 资格编号:s0120523050002 邮箱:zhaikun@tebon.com.cn 张崇欣 资格编号:S0120522100003 邮箱:zhangcx@tebon.com.cn 高嘉麒 资格编号:S0120523070003 邮箱:gaojq@tebon.com.cn 康宇豪 资格编号:S0120524050001 邮箱:kangyh@tebon.com.cn 谷瑜 资格编号:S0120524080002 邮箱:guyu5@tebon.com.cn 研究助理 市场表现 -24% -18% -12% -6% 0% 6% 12% 18% 2023-09 2024-01 2024-05 ...
公用事业行业周报:水泥、钢铁、电解铝拟纳入全国碳市场,碳市场活跃度有望提升
Tebon Securities· 2024-09-16 12:23
[Table_Main] 证券研究报告 | 行业周报 公用事业 2024 年 09 月 16 日 | --- | --- | |------------------|----------------------------------| | | | | | | | 公用事业 | 水泥、钢铁、电解铝拟纳入全国碳市 | | 优于大市(维持) | 场,碳市场活跃度有望提升 | | | 环保与公用事业周报 | 证券分析师 郭雪 资格编号:S0120522120001 邮箱:guoxue@tebon.com.cn 卢璇 资格编号:S0120524050004 邮箱:luxuan@tebon.com.cn 研究助理 刘正 邮箱:liuzheng3@tebon.com.cn 市场表现 -20% -15% -10% -5% 0% 5% 10% 15% 2023-09 2024-01 2024-05 公用事业 沪深300 资料来源:聚源数据,德邦研究所 相关研究 行情回顾:本周各板块涨跌不一,申万(2021)公用事业行业指数下跌 3.4%,环保 行业指数下跌 0.9%。公用事业板块中热电跌幅较小,下跌 1.2%,环保板块中园 ...
一品红:聚焦儿童药和慢病药,创新研发取得阶段性进展
Tebon Securities· 2024-09-16 12:23
[Table_Main] 证券研究报告 | 公司点评 一品红(300723.SZ) 2024 年 09 月 16 日 | --- | --- | |-------------------------------|------------------------------| | 一品红( 买入(维持) | 300723.SZ ):聚焦儿 | | 当前价格 ( 元 ) : 13.46 | | | 所属行业:医药生物 / 化学制药 | 童药和慢病药,创新研发取得阶 | | 证券分析师 | 段性进展 | | 周新明 | | 资格编号:S0120524060001 邮箱:zhouxm@tebon.com.cn 吴明华 资格编号:S0120524050002 邮箱:wumh3@tebon.com.cn 投资要点 事件:公司发布2024年半年报。2024上半年,实现营收9.13亿元(-27.90%), 归母净利润 0.46 亿元(-77.33%),扣非归母净利润 0.35 亿元(-76.16%)。 单 Q2 营业收入为 2.9 亿元,同比下降 47.31%,扣非归母净利润-0.63 亿元, 同比下降 218.91%,环比 ...
公用事业行业ESG周报:碳足迹标识认证试点,碳排放权交易市场覆盖水泥等行业
Tebon Securities· 2024-09-16 12:23
[Table_Main] 证券研究报告 | 行业周报 公用事业 2024 年 09 月 16 日 | --- | --- | --- | |------------------|------------------------------|-------| | 公用事业 ESG | 周报:碳足迹标识认证试点,碳 | | | | | | | | 排放权交易市场覆盖水泥等行业 | | | 优于大市(维持) | | | 证券分析师 郭雪 资格编号:S0120522120001 邮箱:guoxue@tebon.com.cn 卢璇 资格编号:S0120524050004 邮箱:luxuan@tebon.com.cn 研究助理 刘正 邮箱:liuzheng3@tebon.com.cn 市场表现 -20% -15% -10% -5% 0% 5% 10% 15% 2023-09 2024-01 2024-05 公用事业 沪深300 资料来源:聚源数据,德邦研究所 相关研究 1.《环保与公用事业周报-首批CCER 项目公示,海风有望深度受益》, 2024.9.8 2.《穗恒运 A(000531.SZ):上网电 量稳步增长,投资 ...
计算机行业点评:OpenAI o1 大模型推理的划时代革命
Tebon Securities· 2024-09-13 08:28
[Table_Main] 证券研究报告 | 行业点评 计算机 2024 年 09 月 13 日 | --- | --- | |------------------|------------------| | | | | | | | 计算机 OpenAI o1 | 大模型推理的划时 | | 优于大市(维持) | 代革命 | 证券分析师 陈涵泊 资格编号:S0120524040004 邮箱:chenhb3@tebon.com.cn 李佩京 资格编号:S0120524090004 邮箱:lipj@tebon.com.cn 研究助理 王思 邮箱:wangsi@tebon.com.cn 市场表现 -44% -37% -29% -22% -15% -7% 0% 7% 2023-09 2024-01 2024-05 计算机 沪深300 资料来源:德邦研究所,聚源数据 相关研究 1.《朗新集团(300682.SZ):互联网 电视收缩致利润下滑,能源数字化+ 互联网业务快速发展》,2024.9.10 2.《金融信创进一步加速》,2024.9.8 3.《2024 半年报总结:盈利待反转, 算 力 工 业 软 件 信 创 高 景 ...
贵州三力事件点评:控股股东承诺不减持+三年高分红+高额回购,重视投资回报,彰显发展信心
Tebon Securities· 2024-09-12 14:23
Investment Rating - The report maintains a "Buy" rating for Guizhou Sanli (603439.SH) [2] Core Views - The report highlights the commitment of the controlling shareholder not to reduce their stake for 18 months, a three-year high dividend plan, and a significant share buyback program, indicating strong confidence in the company's long-term development and commitment to shareholder returns [3][4] - The company has shown strong operational performance, with a 77% year-on-year revenue growth and a 33% increase in net profit for Q2 2024, reflecting successful integration of acquisitions and a diversified product portfolio [4] - The report projects net profits for 2024-2026 to be CNY 3.5 billion, CNY 4.3 billion, and CNY 5.2 billion respectively, with corresponding P/E ratios of 15, 12, and 10, suggesting the current market valuation is significantly undervalued [4] Summary by Sections Market Performance - The stock has shown a relative performance of +15.93% in September 2023 compared to the CSI 300 index [2] Financial Data - The company reported a total revenue of CNY 1.635 billion in 2023, with projections of CNY 2.593 billion in 2024, CNY 3.140 billion in 2025, and CNY 3.684 billion in 2026 [5][6] - The net profit for 2023 was CNY 293 million, expected to grow to CNY 350 million in 2024, CNY 430 million in 2025, and CNY 520 million in 2026 [5][6] - The gross margin is projected to remain stable around 72.4% to 72.8% over the next few years [6] Operational Highlights - The company has diversified its product offerings across multiple medical fields, including respiratory, gynecology, and cardiovascular departments, reducing reliance on a single product [4] - The integration of subsidiaries has shown positive results, with Dechangxiang achieving a revenue of CNY 97.03 million in H1 2024, a 67.1% increase year-on-year [4] Shareholder Returns - The controlling shareholder has committed to not selling shares for 18 months, and the company plans to distribute at least 50% of its distributable profits as dividends over the next three years [3][4] - A share buyback plan is in place, with an expected buyback amount of CNY 80-120 million, representing 1.09%-1.64% of the total share capital [3]
视源股份:AI教育赋能,海外自有品牌加速
Tebon Securities· 2024-09-12 06:03
Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is a global leader in LCD display main control boards and interactive smart panels, with strong cash flow and a commitment to shareholder returns through dividends [2][4]. - The board card business is expected to recover, and smart controllers are anticipated to provide new growth points [2][4]. - The overseas market for interactive flat panel displays (IFPD) shows significant growth potential, driven by low penetration rates and increasing demand for educational digitalization [3][4]. - Domestic education policies are expected to boost demand for educational tablets, with AI models enhancing the company's competitive edge in the education sector [3][4]. Summary by Sections Company Overview - The company, established in December 2005, specializes in the design, research, and sales of LCD display main control boards and interactive smart panels, with notable brands like Seewo and MAXHUB [10][11]. Business Expansion - The company has diversified its operations into five main business lines, including components, education, enterprise services, and overseas markets, with a strong focus on innovation and digital transformation [12][13]. Financial Performance - The company reported a revenue of 20.17 billion yuan in 2023, a decline of 3.9% year-on-year, with a net profit of 1.37 billion yuan, down 33.9% [15][17]. - For 2024-2026, projected revenues are 22.81 billion, 25.52 billion, and 28.44 billion yuan, with net profits expected to grow to 1.40 billion, 1.68 billion, and 1.98 billion yuan respectively [4][5]. Market Trends - The global TV market is expected to recover in 2024, driven by major sporting events and domestic policies promoting appliance upgrades, which will benefit the company's board card business [22][24]. - The interactive smart panel market is projected to grow significantly, with the company leveraging its leading position to capture market share in emerging regions [3][31]. Innovation and R&D - The company maintains a strong focus on R&D, with over 9,000 patents and a commitment to technological innovation, which is crucial for product upgrades and market competitiveness [19][20]. Dividend Policy - The company has a consistent dividend payout ratio above 30%, with a total dividend of 5.92 billion yuan in 2023, reflecting its strong cash flow management [21][20].
博瑞医药:双靶点GLP-1领衔,由仿制向创新的蜕变
Tebon Securities· 2024-09-12 00:23
[Table_Main] 证券研究报告|公司首次覆盖 博瑞医药(688166.SH) 2024 年 09 月 11 日 证券分析师 周新明 资格编号:S0120524060001 邮箱:zhouxm@tebon.com.cn 陈进 资格编号:S0120521110001 邮箱:chenjing3@tebon.com.cn 李霁阳 资格编号:S0120523080003 邮箱:lijy7@tebon.com.cn 研究助理 市场表现 -26% 0% 26% 51% 77% 103% 129% 154% 博瑞医药 沪深300 | --- | --- | --- | --- | |--------------------------------|----------------|--------------|--------| | 2023-09 \n沪深 300 对比 | 2024-01 \n1M | 2024-05 \n2M | 3M | | 绝对涨幅 (%) | -7.86 | -22.86 | -31.10 | | 相对涨幅 (%) | -3.78 | -16.06 | -20.52 | | 资料来源:德邦 ...
PCB板块:24Q2淡季不淡,24Q3关注增长确定性强的细分赛道
Tebon Securities· 2024-09-11 06:28
[Table_Main] 证券研究报告 | 行业点评 电子 2024 年 09 月 11 日 | --- | --- | --- | |------------------|--------------|----------------------------| | | | | | 电子 | | | | | PCB 板块: | 淡季不淡, 24Q3 | | 优于大市(维持) | | 关注增长确定性强的细分赛道 | 证券分析师 陈蓉芳 资格编号:S0120522060001 邮箱:chenrf@tebon.com.cn 刘琦 资格编号:S0120524090003 邮箱:liuqi3@tebon.com.cn 研究助理 市场表现 电子 沪深300 -31% -24% -18% -12% -6% 0% 6% 12% 2023-09 2024-01 2024-05 资料来源:德邦研究所,聚源数据 相关研究 1.《先进封装助力芯片性能突破, AI 浪潮催化产业链成长》,2024.9.6 2.《IC 设计公司中报总结:业绩开始 改善,周期拐点已至》,2024.9.5 3.《中科飞测(688361.SH):业绩短期 承压 ...
朗姿股份:24H1业绩稳健,并表两家机构夯实全国化布局
Tebon Securities· 2024-09-11 06:23
Investment Rating - The report maintains an "Accumulate" rating for the company [2] Core Views - The company's performance in H1 2024 is stable, with a revenue of 2.689 billion yuan, a year-on-year increase of 6.21%, and a net profit attributable to the parent company of 152 million yuan, up 1.14% year-on-year [3] - The medical beauty business shows robust growth, with revenue reaching 1.194 billion yuan in H1 2024, a year-on-year increase of 6.02% [3] - The women's clothing segment continues to grow, with revenue of 1.012 billion yuan in H1 2024, a year-on-year increase of 11.41% [3] - The company is actively expanding its national footprint through acquisitions and partnerships in the medical beauty sector [3] Summary by Sections Financial Performance - In H1 2024, the company reported a revenue of 2.689 billion yuan, with a year-on-year growth of 6.21%. The net profit attributable to the parent company was 152 million yuan, reflecting a 1.14% increase year-on-year. The net profit after deducting non-recurring items was 140 million yuan, up 11.49% year-on-year [3] - For Q2 2024, the revenue was 1.289 billion yuan, a year-on-year increase of 1.07%, while the net profit was 70 million yuan, down 12.03% year-on-year [3] Medical Beauty Business - The medical beauty segment generated 1.194 billion yuan in revenue in H1 2024, with a year-on-year increase of 6.02%. The segment's gross margin was 54.23%, a decrease of 0.70 percentage points year-on-year [3] - The company has established 38 medical beauty institutions and completed the acquisition of Zhengzhou Jimei, contributing 57 million yuan to the medical beauty revenue in H1 2024 [3] - The company has set up seven medical beauty acquisition funds with a total scale of 2.837 billion yuan [3] Clothing Business - The women's clothing segment achieved a revenue of 1.012 billion yuan in H1 2024, with a year-on-year increase of 11.41%. The online sales channel contributed 385 million yuan, a year-on-year increase of 13.41% [3] - The children's clothing segment reported a revenue of 450 million yuan in H1 2024, a year-on-year decrease of 4.13% [3] Investment Outlook - The company is expected to see revenue growth from 5.988 billion yuan in 2024 to 7.238 billion yuan in 2026, with net profit projected to increase from 302 million yuan to 445 million yuan during the same period [3][5] - The report anticipates a compound annual growth rate (CAGR) of 34.3% for net profit from 2024 to 2026 [3]